61 related articles for article (PubMed ID: 27531800)
1. [Effect of Tyrosine Phosphorylation Sites of Oncogenic Protein NPM-ALK on Cell Cycle and Its Related Mechanisms].
Hu LL; Zhen H; Zhang XN; Zhou L; Amin HM; Shi P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1201-5. PubMed ID: 27531800
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
3. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
[TBL] [Abstract][Full Text] [Related]
4. NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair.
Bone KM; Wang P; Wu F; Wu C; Li L; Bacani JT; Andrew SE; Lai R
Blood Cancer J; 2015 May; 5(5):e311. PubMed ID: 25978431
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
[TBL] [Abstract][Full Text] [Related]
7. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
[TBL] [Abstract][Full Text] [Related]
8. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.
Vishwamitra D; Curry CV; Alkan S; Song YH; Gallick GE; Kaseb AO; Shi P; Amin HM
Mol Cancer; 2015 Feb; 14():53. PubMed ID: 25884514
[TBL] [Abstract][Full Text] [Related]
9. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R
Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
[TBL] [Abstract][Full Text] [Related]
10. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK
Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM
Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340
[TBL] [Abstract][Full Text] [Related]
11. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T
Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786
[TBL] [Abstract][Full Text] [Related]
12. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
13. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
[TBL] [Abstract][Full Text] [Related]
14. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner.
Slupianek A; Skorski T
Exp Hematol; 2004 Dec; 32(12):1265-71. PubMed ID: 15588951
[TBL] [Abstract][Full Text] [Related]
15. SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein.
Vishwamitra D; Curry CV; Shi P; Alkan S; Amin HM
Neoplasia; 2015 Sep; 17(9):742-754. PubMed ID: 26476082
[TBL] [Abstract][Full Text] [Related]
16. Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL).
Ritter U; Damm-Welk C; Fuchs U; Bohle RM; Borkhardt A; Woessmann W
Oligonucleotides; 2003; 13(5):365-73. PubMed ID: 15000827
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA.
Marzec M; Liu X; Wong W; Yang Y; Pasha T; Kantekure K; Zhang P; Woetmann A; Cheng M; Odum N; Wasik MA
Oncogene; 2011 Mar; 30(11):1372-8. PubMed ID: 21102525
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
[TBL] [Abstract][Full Text] [Related]
19. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
20. [Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains].
Gu L; Li JF; Gao J; Zhu YP; Li Q; Jia CS; Zhou CY; Ma ZG
Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):662-6. PubMed ID: 19176057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
